Invivyd, Inc. Common Stock (IVVD) is a publicly traded Healthcare sector company. As of May 21, 2026, IVVD trades at $1.13 with a market cap of $332.91M and a P/E ratio of -3.52. IVVD moved +4.33% today. Year to date, IVVD is -57.25%; over the trailing twelve months it is +34.70%. Its 52-week range spans $0.35 to $3.07. Analyst consensus is strong buy with an average price target of $10.00. Rallies surfaces IVVD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Invivyd’s Q1 Revenue Drops to $13.7M, 22% PEMGARDA Growth Fails to Offset EPS Miss: Invivyd’s Q1 loss widened to $0.13 per share on $13.74 million revenue, missing estimates of $0.08 loss and $18.04 million revenue. PEMGARDA net product revenue rose 22% year‐over‐year to support a reduced quarterly loss despite higher operating expenses driven by VYD2311 clinical trial spending.
| Metric | Value |
|---|---|
| Price | $1.13 |
| Market Cap | $332.91M |
| P/E Ratio | -3.52 |
| EPS | $-0.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.07 |
| 52-Week Low | $0.35 |
| Volume | 1.68K |
| Avg Volume | 0 |
| Revenue (TTM) | $53.43M |
| Net Income | $-52.49M |
| Gross Margin | 0.00% |
3 analysts cover IVVD: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.00.